Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Pediatrics
Pediatrics
This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.
Pediatrics
N/A
Friedman, Debra
NCT00736749
COGALTE05N1
Ocular Tumor Tissue Acquisition to Study Biologic Correlates of Disease
Multiple Cancer Types
Pediatrics,
Retinoblastoma (Pediatrics)
N/A
Daniels, Anthony
VICCPED16115
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Pediatric Leukemia
Pediatric Leukemia
This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in Part 1.
Pediatric Leukemia
II
Friedman, Debra
NCT02723994
VICCPED16131
Retinoblastoma Survivor Study (RBSS)
Retinoblastoma (Pediatrics)
Retinoblastoma (Pediatrics)
Retinoblastoma (Pediatrics)
N/A
Friedman, Debra
VICCREACH1447
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients with Non-high Risk Neuroblastoma
Neuroblastoma (Pediatrics)
Neuroblastoma (Pediatrics)
This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma. Sometimes a tumor may not need treatment until it progresses. In this case, observation may be sufficient. Measuring biomarkers in tumor cells may help plan when effective treatment is necessary and what the best treatment is. Response and biology-based risk factor-guided therapy may be effective in treating patients with non-high risk neuroblastoma and may help to avoid some of the risks and side effects related to standard treatment.
Neuroblastoma (Pediatrics)
III
Pastakia, Devang
NCT02176967
COGANBL1232
Infectious Disease Outcomes in Pediatric Oncology Patients
Multiple Cancer Types
Miscellaneous,
Pediatrics
N/A
Esbenshade, Adam
VICCPED14127
Impact of a PCRC-Supported Legacy Intervention in Pediatric Palliative Care
Miscellaneous
Miscellaneous
Miscellaneous
N/A
Foster Akard, Terrah
VICCPED14130
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients with Down Syndrome
This phase III trial studies response-based chemotherapy in treating newly diagnosed acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Response-based chemotherapy separates patients into different risk groups and treats them according to how they respond to the first course of treatment (Induction I). Response-based treatment may be effective in treating acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome while reducing the side effects.
Not Available
III
Friedman, Debra
NCT02521493
COGAAML1531
Neuroblastoma Biology Studies
Multiple Cancer Types
Neuroblastoma (Pediatrics),
Pediatrics
N/A
Pastakia, Devang
NCT00256763
CCGANBL00B1
Key Adverse Events after Childhood Cancer
Multiple Cancer Types
Miscellaneous,
Pediatric Leukemia,
Pediatrics
N/A
Friedman, Debra
COGALTE03N1
